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INTRODUCTION
Juvenile rheumatoid arthritis is the most
common cause of chronic arthritis in children.
It is defined as an arthritis complaint lasting 6
weeks or longer in patients 16 years of age
and younger that has no known etiology. This
is a diagnosis of exclusion, so other causes of
chronic arthritis must be ruled out.1,2
Juvenile rheumatoid arthritis has been
divided into subtypes, but we are still unable
to identify those children who will progress
to poor outcomes and might benefit from
more aggressive therapy.3 Many children with
juvenile rheumatoid arthritis respond to a lim-
ited course of nonsteroidal anti-inflammatory
drugs, especially those with oligoarticular on-
set. Sometimes, these drugs associated with
intra-articular corticosteroid are often the only
treatment needed.4 Most patients with sys-
temic or polyarticular onset need second-line
medication. Hydroxychloroquine or meth-
otrexate is useful as an adjunct to nonsteroi-
dal anti-inflammatory drugs. Glucocorticoids
have been tried with good results in juvenile
rheumatoid arthritis, but their side effect pro-
file precludes routine use. They should be used
for shorter periods of time. Immunosuppres-
sive drugs are being increasingly utilized early
on in patients with juvenile rheumatoid ar-
thritis who need aggressive therapy.
Refractory juvenile rheumatoid arthritis
should be considered when the disease does
not respond to high doses of methotrexate (1
mg/kg/week subcutaneously). In such cases,
therapies involving combinations of drugs or
more aggressive therapies like intravenous
methylprednisolone and cyclophosphamide
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CONTEXT: Patients with refractory juvenile idiopathic
arthritis can benefit from aggressive therapy.
CASE REPORT: We followed the clinical course of 4
patients (2 male, 2 female) aged 9.1-17.8 years
(mean of 14.5 years) with polyarticular onset of
juvenile rheumatoid arthritis and one 16-year-
old boy with juvenile spondyloarthropathy asso-
ciated with inflammatory bowel disease. All the
juvenile rheumatoid arthritis patients fulfilled the
diagnostic criteria established by the American
College of Rheumatology. All patients had unre-
mitting arthritis despite maximum therapy. All
patients began receiving treatment using intra-
venous cyclophosphamide at 500-750 mg/m2
and intravenous methylprednisolone at 30 mg/
kg, for 3 days monthly (1 g maximum). The pa-
tients received between 3 and 11 monthly treat-
ments, and/or 3-5 treatments every two months
for 12 months, according to the severity of the
disease and/or response to the therapy. All but
one patient were evaluated retrospectively at the
start (time 0) and 6 months (time 1), and 12
months (time 2) after the beginning of the treat-
ment. A rapid and clinically significant suppres-
sion of systemic and articular manifestations was
seen in all patients. Our results showed the
favorable effect of this treatment on the clinical
and some laboratory manifestations of juvenile
idiopathic arthritis.
KEY WORDS: Rheumatoid athritis. Juvenile rheuma-
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can be considered, since the use of biological
agents is not possible for most patients.
Our purpose was to clinically and sero-
logically evaluate the treatment outcomes from
four patients with a severe form of juvenile
rheumatoid arthritis and one with juvenile
spondyloarthropathy, treated using intrave-
nous pulses of cyclophosphamide and meth-
ylprednisolone and high doses of subcutane-
ous methotrexate over periods ranging from
8 to 11 months.
○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○ ○
CASE REPORT
Patient 1
A 9.1-year-old boy had developed rash,
fever and polyarthritis in the large joints of
the cervical spine, shoulders, wrists and an-
kles at the age of 2.6 years. He presented per-
sistent anemia, leukocytosis and thrombocy-
tosis, and an elevated erythrocyte sedimenta-
tion rate, despite therapy using prednisone,
nonsteroidal anti-inflammatory drugs and
methotrexate. He maintained fever, rash and
arthritis when we started a course of immu-
noglobulin IV monthly, with cyclosporin and
pulse therapy using methylprednisolone, with
no improvement. Because of persistent active
disease, we started pulses of intravenous meth-
ylprednisolone with cyclophosphamide (11
monthly treatments). The patient showed
good response with improvement in the clini-
cal and laboratory parameters.
Patient 2
A 14.3-year-old girl had started fever and
polyarthritis at the age of 2 years. She presented
small joint disease involving the hands and feet.
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The cervical spine, shoulders, elbows, wrists,
hips, knees and ankles were also involved. She
presented anemia, leukocytosis, thrombocyto-
sis and an elevated erythrocyte sedimentation
rate. She used prednisone, nonsteroidal anti-
inflammatory drugs, immunoglobulin IV
monthly and methotrexate, with no clinical and
laboratory improvement. She developed toxic-
ity with elevation of hepatic enzyme levels, and
methotrexate was discontinued. Cyclosporin
was introduced but the patient persisted with
disease activity. We started pulses of intrave-
nous methylprednisolone and cyclophospha-
mide (3 monthly and 3 bimonthly treatments).
The patient showed improvement in the clini-
cal and laboratory activity.
Patient 3
This 15.5-year-old girl had started poly-
articular onset disease at the age of 1.4 years.
She presented fever and rash, with small and
large joint disease involving the hands, feet,
shoulders, elbows, wrists, hips and knees. She
had unremitting disease despite therapy with
prednisone, nonsteroidal anti-inflammatory
drugs, methotrexate, azathioprine and pulses
of methylprednisolone. She was treated using
pulse therapy of intravenous methylpred-
nisolone with cyclophosphamide (5 bi-
monthly treatments), with improvement in
her joint symptoms and laboratory results.
Patient 4
This 17.8-year-old boy had presented with
polyarthritis in the large joints of the cervical
spine, shoulders, elbows, wrists, hips, knees
and ankles at the age of 7 years. He had not
obtained improvement with prednisone, non-
steroidal anti-inflammatory drugs, methotrex-
ate, hydroxychloroquine and pulses of meth-
ylprednisolone. He started a course of azathio-
prine because of his unremitting disease. The
patient showed improvement after treatment
using pulse therapy of intravenous methyl-
prednisolone with cyclophosphamide (5 bi-
monthly treatments).
Patient 5
A 16-year-old boy had developed spondy-
loarthropathy associated with inflammatory
bowel disease at the age of 2 years. He pre-
sented involvement of elbows, wrists and
knees. He was initially treated with pred-
nisone, nonsteroidal anti-inflammatory drugs
and methotrexate and then with sulfasalazine
and azathioprine, with no improvement. He
persisted with active disease until the begin-
ning of pulse therapy of intravenous methyl-
prednisolone with cyclophosphamide (8
monthly treatments). He showed improve-
ment in the number of joints with active dis-
ease and the erythrocyte sedimentation rate.
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RESULTS
Characteristics of the five patients are
shown in Table 1. Disease onset occurred be-
tween the ages of 1.4 and 7.0 years (mean of
3.0 years) and patient ages at the time of the
study were 9.1 to 17.8 years (mean of 14.5
years). Disease duration was considered to be
the period of time from the first clinical mani-
festations until the beginning of the therapy
(methylprednisolone, cyclophosphamide and
methotrexate). It ranged from 6.5 to 14.1 years
(mean of 11.5 years).
All the juvenile rheumatoid arthritis patients
presented polyarticular onset. Each patient re-
ceived between 3 and 11 monthly treatments of
intravenous methylprednisolone and cyclophos-
phamide, and 3-5 intravenous methylpred-
nisolone and cyclophosphamide infusions every
two months for 12 months (Table 1). Clinical
and serological improvement was noted in four
patients (Table 2). The number of joints with
active disease was reduced in four patients, as
was the erythrocyte sedimentation rate in four
patients. Hemoglobin levels increased in four
patients. All patients required lower doses of
corticosteroids and two discontinued this medi-
cation (Table 2). During the evaluation period,
only one patient underwent modification of the
therapy (azathioprine use), with no improve-
ment. Two patients took cyclosporin, two pa-
tients azathioprine, one patient intravenous im-
munoglobulin and one patient sulfasalazine over
the whole follow-up period (Table 1). With re-
gard to side effects, patient 4 presented nausea
and patient 1 hypertension. Improvement was
noted in both patients after symptomatic therapy.
No patients in this study went into remission.
All subjects were at or below the 10th percentile
in height for age.
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DISCUSSION
The aim in treating juvenile rheumatoid
arthritis is to minimize discomfort, reduce
disability, prevent joint destruction, and maxi-
mize physical, social and emotional develop-
ment. However, successful management of
severe juvenile rheumatoid arthritis remains a
challenge in pediatric rheumatology.5
Pulse therapy using methylprednisolone
Table 1. Clinical and epidemiological characteristics, medications in use and treatment frequency of
5 patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Sex M F F M M
Age, in years 9.1 14.3 15.5 17.8 16.0
JRA subtype polyarticular polyarticular polyarticular polyarticular -
Age at onset, years 2.6 2.0 1.4 7.0 2.0
Duration of disease, in years 6.5 12.3 14.1 10.8 14.0
Medications in use cyclosporin cyclosporin azathioprine azathioprine  sulfasalazine
2.8 mg/kg/day 4.5 mg/kg/day 2.2 m/kg/day; 2.0 m/kg/day; 30 mg/kg/day;
MTX MTX MTX MTX
0.9 mg/kg/week; 0.9 mg/kg/week 0.9 mg/kg/week 1 mg/kg/week
immunoglobulin 2 g/kg
Pulses CYC and MP IV CYC and MP IV CYC and MP IV CYC and MP IV CYC and MP IV
monthly, for 11 months monthly, for 3 months, bimonthly for bimonthly for monthly, for
and bimonthly 5 months 5 months 8 months
 for 3 months
Total of pulses 11 6 5 5 8
JRA = juvenile rheumatoid arthritis; MTX = methotrexate; M = male; F = female; IV = intravenous; CYC = cyclophosphamide; MP = methylprednisolone.
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is an alternative to oral corticosteroids, in or-
der to reduce the side effects. Job-Deslandre
and Menkes6 retrospectively evaluated the re-
sults from methylprednisolone pulses in 15
children with chronic arthritis (13 cases of
juvenile rheumatoid arthritis and two cases of
spondyloarthropathy). Methylprednisolone
succinate was administered at a dosage of 700
mg/m2 by an intravenous infusion pump on
3 consecutive days. A dramatic clinical im-
provement was obtained in 12/15 cases by day
4. In seven cases, multiple pulses (between two
and eight courses) were administered to ob-
tain better control of the disease and a decrease
in the daily dosage of corticosteroids. The
authors observed only mild and transient side
effects and a decrease in the previous side ef-
fects from the corticosteroids (especially
growth retardation).
Azathioprine and cyclophosphamide have
been used in the treatment of juvenile rheu-
matoid arthritis but their potential toxicity is
greater. The benefits from pulse cyclophospha-
mide in comparison with oral cyclophospha-
mide include reduction in the total dose and
the risk of side effects. Adequate hydration can
be provided, so as to protect the bladder from
hemorrhagic cystitis.7 Other “disease-modify-
ing therapies” that are being tried in juvenile
rheumatoid arthritis include hydroxy-
chloroquine, sulfasalazine, intravenous immu-
noglobulin, cyclosporin, and combination
therapy.3,8,9 The most commonly used disease-
modifying antirheumatic drug presently used
in juvenile rheumatoid arthritis is methotrex-
ate, particularly in polyarticular and systemic
juvenile rheumatoid arthritis. It has been
shown to be safe and effective in retrospective
studies, clinical practice and controlled tri-
als.10,11 Serious long-term toxicity appears to
be infrequent.10,11
Pulse cyclophosphamide with methyl-
prednisolone has been proposed for the treat-
ment of severe systemic-onset juvenile rheu-
matoid arthritis.12 Wallace and Sherry13 stud-
ied four children (two male, two female) with
systemic-onset juvenile rheumatoid arthritis,
joint destruction and polyarthritis that re-
mained active despite maximal therapy with
combination of drugs. Intravenous cyclophos-
phamide (500-1000 mg/m2) and methylpred-
nisolone 30 mg/kg/day (1 g maximum) were
given monthly. Patients received six to ten
monthly treatments followed by two to thir-
teen subsequent treatments every two to three
months. All patients showed clinical improve-
ment with 12-20 intravenous pulses. Three
patients achieved disease remission despite the
discontinuation of cyclophosphamide.
Shaikov et al.14 evaluated the effectiveness of
pulse therapy consisting of methylpred-
nisolone 30 mg/kg/day for three consecutive
days, cyclophosphamide 400 mg/m2 and
methotrexate 10 mg/m2 in 18 patients (10
male, 8 female) with systemic juvenile rheu-
matoid arthritis. The children received pulse
1 2
Table 2. Clinical and laboratory characteristics, and corticosteroid doses at the start and 6 months and 1 year after the start of treatment
(cyclophosphamide + methylprednisolone + methotrexate), of 5 patients with juvenile rheumatoid arthritis and juvenile spondyloarthropathy
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Months after start of treatment 0 6 12 0 6 12 0 6 12 0 6 12 0 6 12
Number of active
joints 1 1 2 8 2 1 5 1 1 3 7 2 5 3 3
Steinbrocker II I IV II IV II III II II II
functional class
Hb, g/100 ml 9.8 12.7 13.0 7.3 9.8 9.7 10.1 9.6 10.2 12.8 8.2 9.2 8.2 9.7 8.8
Htc, % 31 40.0 39.7 24 30 31.4 34 32 31 41 28 29 27 32 30.5
WBC, x1000/cm2 9.7 11.3 6.4 15.0 16.4 10.8 9.8 4.4 6.9 11.3 12.4 11.0 5.5 5.4 3.5
Platelets, 117 442 418 762 704 599 519 290 352 403 709 303 240 280 241
x1000/cm2
ESR, mm/hour 71 22 22 125 91 60 40 4 48 57 26 45 54 12 14
CS, mg/kg/day 0.28 0.17 0.14 0.41 0.15 0 0.21 0.20 0.08 0.34 0.17 0.09 0.20 0 0
Hb = hemoglobin; Htc = hematocrit; WBC = white blood cell count; ESR = Westergren erythrocyte sedimentation rate; CS = corticosteroids.
therapy every three months in an open trial
of 12 months duration. A rapid and clinically
significant suppression of systemic and articu-
lar manifestations was seen in all patients. A
significant decrease in laboratory indices of
disease activity was also observed. These stud-
ies and ours suggest that the addition of pulse
therapy of cyclophosphamide and methyl-
prednisolone to the methotrexate treatment
is potentially useful in patients with resistant
polyarticular or systemic-onset disease.
In our study, all patients had been using
methotrexate prior to this treatment, with no
results. It was only when we associated intra-
venous cyclophosphamide and methylpred-
nisolone that we observed a notable clinical
and laboratory improvement. No significant
side effects were observed during the study.
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CONCLUSION
Our results showed the favorable effect of
this treatment on the clinical and some labora-
tory manifestations of juvenile idiopathic ar-
thritis. The reduction in the daily dose of oral
steroids must be considered one of the most
important effects among such patients. These
data support the need for controlled trials us-
ing cyclophosphamide, methylprednisolone
and methotrexate in a larger cohort of patients
with juvenile idiopathic arthritis, so as to de-
termine the safety, efficacy, and disease-modi-
fying effects in this inflammatory condition.
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CONTEXTO: Pacientes com artrite idiopática
juvenil refratária podem se beneficiar com
uma terapia mais agressiva.
RELATO DE CASO: A artrite reumatóide juve-
nil é a causa mais comum de artrite crônica
em crianças definida como artrite por mais de
seis semanas em pacientes com idade igual ou
inferior a 16 anos. Ela é considerada refratária
quando não responde ao tratamento com
metotrexato em doses elevadas (1 mg/kg/se-
mana subcutâneo). Nesses casos, terapias de
associação de medicamentos ou terapias mais
agressivas, como pulso de solumedrol e
ciclofosfamida podem ser indicadas. Quatro
pacientes com artrite reumatóide juvenil e um
com espondiloartropatia juvenil associada a do-
ença inflamatória intestinal foram acompanha-
dos em nosso serviço. Todos receberam
pulsoterapia com ciclofosfamida intravenosa
(500-750 mg/m2) e metilprednisolona intra-
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venosa (30 mg/kg/dia). Todos os pacientes re-
ceberam entre 3 e 11 pulsos mensais e/ou 3 a
5 pulsos a cada 2 meses por um período de 12
meses de acordo com a gravidade da doença
e/ou a resposta à terapia. Todos, exceto um
paciente, foram avaliados retrospectivamente
no início (tempo 0), 6 meses (tempo 1) e 12
meses (tempo 2) após iniciar o tratamento.
Uma rápida e significante supressão das ma-
nifestações articulares e sistêmicas foi observa-
da em todos os pacientes. Nossos resultados
mostraram um efeito favorável deste esquema
terapêutico nas manifestações clínicas e
laboratoriais da artrite idiopática juvenil. A
redução da dose diária de corticóide oral deve
ser considerada um dos mais importantes efei-
tos nestes pacientes.
PALAVRAS-CHAVE: Artrite reumatóide.  Artri-
te reumatóide Juvenil. Artrite. Metil-
prednisolona. Ciclofosfamida. Metotrexate.
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